Abstract:Introduction: Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. However, this degradation is not a sustained and efficient process. Therefore, we designed a cyclic peptide PROTAC to achieve this efficient anti-PD-L1 effect. Methods: We designed and synthesized an improvement in linear peptide PROTAC targeting palmitoyltransferase DHHC3, and used disulfide bonds to stabilize the continuous N- and C-termini of the peptides to maintain their structure. Cellular and molecular biology techniques were used to test the effect of this cyclic peptide on PD-L1. Results: In human cervical cancer cells, our cyclic peptide PROTAC can significantly downregulate palmitoyl transferase DHHC3 and PD-L1 expressions. This targeted degradation effect is enhanced with increasing doses and treatment duration, with a DC50 value much lower than that of linear peptides. Additionally, flow cytometry analysis of fluorescence intensity shows an increase in the amount of cyclic peptide entering the cell membrane with prolonged treatment time and higher concentrations. The Cellular Thermal Shift Assay (CETSA) method used in this study indicates effective binding between our novel cyclic peptide and DHHC3 protein, leading to a change in the thermal stability of the latter. The degradation of PD-L1 can be effectively blocked by the proteasome inhibitor MG132. Results from clone formation experiments illustrate that our cyclic peptide can enhance the proliferative inhibition effect of cisplatin on the C33A cell line. Furthermore, in the T cell-C33A co-culture system, cyclic peptides target the degradation of PD-L1, thereby blocking the interaction between PD-L1 and PD-1, and promoting the secretion of IFN-γ and TNF-α in the co-culture system supernatant. Conclusion: Our results demonstrate that a disulfide-bridged cyclic peptide PROTAC targeting palmitoyltransferase can provide a stable and improved anti-PD-L1 activity in human tumor cells.

Photocleavable cyclic peptide for modifying protein − peptide interaction

Photoactive Properties of Supramolecular Assembled Short Peptides.

Peptide Macrocyclization via Intramolecular Interception of Visible-Light-Mediated Desulfurization

Peptide Macrocyclisation via Intramolecular Interception of Visible-Light-Mediated Desulfurisation

Cyclic Peptide Linker Design and Optimization by Molecular Dynamics Simulations

Histidine-Iridium(Iii) Coordination-Based Peptide Luminogenic Cyclization and Cyclo-Rgd Peptides for Cancer-Cell Targeting

Supramolecular Peptide Constructed by Molecular Lego Allowing Programmable Self-Assembly for Photodynamic Therapy

A Photo‐Switchable Peptide Fibril Esterase

Isothiocyanate Enabled Versatile Cyclizations of Phage Dis-played Peptides for the Discovery of Macrocyclic Binders

A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells

A Caged Phosphopeptide‐Based Approach for Photochemical Activation of Kinases in Living Cells

PHOTACs enable optical control of protein degradation

A Sulfonium Tethered Peptide Ligand Rapidly and Selectively Modifies Protein Cysteine in Vicinity

Quantitative control of subcellular protein localization with a photochromic dimerizer

Efficient Delivery of Cyclic Peptides into Mammalian Cells with Short Sequence Motifs

An N-ortho-nitrobenzylated benzanilide amino acid enables control of the conformation and membrane permeability of cyclic peptides

Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation

Peptide-Carbazolyl Cyanobenzene Conjugates: Enabling Biomolecule Functionalization via Photoredox and Energy Transfer Catalysis

Proximity-driven site-specific cyclization of phage-displayed peptides

Computational design of cyclic peptides to inhibit protein-peptide interactions

Macrocyclization of an all-d linear α-helical peptide imparts cellular permeability